SMP-300

a Na+/H+ exchange inhibitor, on myocardial ischemia and experimental angina models in rats; structure in first source

Also Known As:

N-(aminoiminomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo(3,2,1-kl)(1)benzazocine-2-carboxamide monomethanesulfonate monohydrate

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Acidosis 10/01/2000 - "SMP-300 concentration-dependently inhibited recovery from acidosis in rat myocytes, and its IC50 for Na+/H+ exchange was 6 nM. In comparison, its IC50s for Na+/Ca2+ exchange and for the Na+ channel were >1000 nM, and those for other channels or receptors tested were >10,000 nM. In rat isolated perfused hearts, SMP-300 (10(-8)-10(-7) M), administered only at preischemia and not during reperfusion, significantly improved the postischemic recovery of cardiac function. "
2.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/2000 - "Effect of SMP-300, a new Na+/H+ exchange inhibitor, on myocardial ischemia and experimental angina models in rats."
3.	Myocardial Infarction 02/01/2002 - "Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats." 02/01/2002 - "SMP-300 (1 mg/kg, p.o.) reduced myocardial infarct size after 40 min of coronary artery occlusion followed by 24 h of reperfusion, but nifedipine (3 mg/kg, p.o.) or propranolol (100 mg/kg, p.o.) did not. " 02/01/2002 - "The effects of SMP-300, an orally active, potent, and selective Na+/H+ exchange inhibitor, were evaluated and compared with those of nifedipine, propranolol, and nicorandil on three experimental angina models and on myocardial infarction in rats. "